On October 12, 2023, an unusual order came down from the European Commission (EC). The EC commanded Illumina to dissolve its completed acquisition of the cancer-test provider GRAIL Inc., marking the first occurrence in history of the EC demanding the reversal of an acquisition. This bold move unfurls a new phase in the continuous narrative surrounding Illumina and GRAIL, which has been unraveling for considerably more than two years.
This narrative started when Illumina, a global leader in DNA sequencing and array-based technologies, announced its plans to acquire GRAIL, a healthcare company whose mission is to detect cancer early before symptoms appear using data and science. However, the transaction soon immediately sparked antitrust concerns from the EC, leading to a lengthy investigation and culminating in this unprecedented order to unwind the transaction.
The EC’s order is consequential and catalyst for a plethora of questions: What is the future of Illumina and GRAIL? How will this order impact the field of preventative healthcare and the business operations of Illumina and GRAIL? What does this mean for future M&A activity in the healthcare and tech industries? While these questions remain unanswered at present, it is clear that this unprecedented move by the EC embodies a significant shift in the dynamics of M&A transactions and will influence the course of similar cases in the future.
Read more about the situation here.